Skip to main content

Table 1 Group comparisons of demographic characteristics, causes of delirium, medication, and number of subjects assessed

From: Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium

Characteristic

Haloperidol

Risperidone

Olanzapine

Quetiapine

Total

Sig.

  

N = 23

N = 21

N = 18

N = 18

N = 80

 

Age, year

74.0 ± 9.9

70.1 ± 9.5

69.5 ± 15.9

73.3 ± 10.7

71.8 ± 11.5

0.522

Education, year

5.8 ± 4.5

8.7 ± 6.9

8.5 ± 6.4

7.3 ± 3.9

7.5 ± 5.6

0.327

Gender, male

12(52.2)

8(38.1)

8(44.4)

8(44.4)

36(45)

0.828

Number of contributing causes of delirium

1.8 ± 0.5

1.9 ± 0.7

1.9 ± 0.4

2.0 ± 0.8

1.9 ± 0.6

0.783

Definite cause of delirium

      

Metabolic/endocrine

6(26.0)

8(38.0)

4(22.2)

5(27.7)

23(28.7)

0.759

Systemic infection

4(17.3)

3(14.2)

3(16.6)

4(22.2)

14(17.5)

0.957

Systemic neoplasm

6(26.0)

1(4.7)

3(16.6)

2(11.1)

12(15.0)

0.260

Cerebrovascular

3(13.0)

3(14.2)

0(0.0)

3(16.6)

9(11.2)

0.328

Organ insufficiency

3(13.0)

3(14.2)

8(44.4)

2(11.1)

16(20.0)

0.059

Others

1(4.3)

3(14.2)

0(0.0)

2(11.1)

6(7.5)

0.354

Dose, mg/day

1.2 ± 0.4

1.1 ± 0.3

2.9 ± 1.0

47.9 ± 17.1

  

Chlorpromazine equivalent dose, mg/day

60.0 ± 21.4

56.3 ± 16.8

59.8 ± 20.5

63.9 ± 22.8

59.8 ± 20.4

0.192

Duration of medication, day

4.7 ± 1.6

5.1 ± 1.3

5.3 ± 1.1

4.8 ± 1.7

4.9 ± 1.5

0.655

Number of subjects assessed,

Baseline

23(100.0)

21(100.0)

18(100.0)

18(100.0)

80(100.0)

 
 

Day 2

18(78.2)

21(100.0)

18(100.0)

15(83.3)

72(90.0)

 

Day 4

16(69.5)

18(85.7)

15(83.3)

12(66.6)

61(76.2)

 
 

Day 6

14(60.8)

14(66.6)

13(72.2)

12(66.6)

53(66.2)

 
  1. Data were presented as mean ± SD or N(%).